Therapeutic effect of two altered peptide ligands derived from the human heat shock protein 60 in experimental models of rheumatoid arthritis

Biotecnologia Aplicada

Volumn 30, Issue 2, 2013, Pages 153-156

  Domínguez, María Del C ^a   Lorenzo, Norailys ^a   Barberá, Ariana ^a   Padrón, Gabriel ^a   Torres, Ana María ^b   Hernández, María V ^b   Hernández, Isabel ^b   Gil, Rafael ^b   Sánchez, Aniel ^a   Besada, Vladimir ^a   González, Luis J ^a   Garay, Hilda ^a   Reyes, Osvaldo ^a   Pérez, Ever ^a   López, Matilde ^a   Yuliet, Mazola ^a   Cosme, Karelia ^a   Ancizar, Julio ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Hospital Clinico Quirurgico   (Cuba)

Author keywords

Adjuvant induced arthritis; Altered peptide ligand; Collagen induced arthritis; Hhsp60; Immune tolerance; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

ALTERED PEPTIDE LIGAND 1; ALTERED PEPTIDE LIGAND 2; CHAPERONIN 60; EPITOPE; INTERLEUKIN 10; INTERLEUKIN 17; METHOTREXATE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; EX VIVO STUDY; EXPERIMENTAL MODEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

EID: 84884187585     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
2. Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today. 2007;12(3-4):125-31.
3. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol. 2009;5(10):531-41.
4. Satpute SR, Durai M, Moudgil KD. Antigen-specifi c tolerogenic and immunomodulatory strategies for the treatment of autoimmune arthritis. Semin Arthritis Rheum. 2008;38(3):195-207.
5. van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005;5(4):318-30.
6. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87.
7. Prakken BJ, Roord S, van Kooten PJ, Wagenaar JP, van Eden W, Albani S, et al. Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope. Arthritis Rheum. 2002;46(7):1937-46.
8. Huurman VA, van der Meide PE, Duinkerken G, Willemen S, Cohen IR, Elias D, et al. Immunological effi cacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol. 2008;152(3):488-97.
9. Bielekova B, Martin R. Antigen-specifi c immunomodulation via altered peptide ligands. J Mol Med (Berl). 2001;79(10): 552-65.
10. Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V. Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics. 2008;9 Suppl 12:S22.
11. Garrood T, Pitzalis C. Targeting the infl amed synovium: the quest for specifi city. Arthritis Rheum. 2006;54(4):1055-60.
12. van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+) CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fl uid. Arthritis Rheum. 2004;50(9):2775-85.
13. Choy EH, Panayi GS. Cytokine pathways and joint infl ammation in rheumatoid arthritis. N Engl J Med. 2001; 344(12): 907-16.
14. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue infl ammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-41.
15. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-defi cient mice. J Immunol. 2003;171(11):6173-7.